Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1976 1
1982 2
1983 3
1984 2
1985 5
1986 1
1987 1
1988 4
1989 8
1990 6
1991 7
1992 7
1993 3
1994 12
1995 13
1996 13
1997 13
1998 12
1999 13
2000 16
2001 9
2002 24
2003 28
2004 36
2005 34
2006 37
2007 41
2008 48
2009 47
2010 48
2011 50
2012 56
2013 71
2014 64
2015 54
2016 67
2017 52
2018 55
2019 53
2020 60
2021 52
2022 21
Text availability
Article attribute
Article type
Publication date

Search Results

1,019 results
Results by year
Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Double-blind, Randomized, Placebo-controlled Trial With N-acetylcysteine for Treatment of Severe Acute Respiratory Syndrome Caused by Coronavirus Disease 2019 (COVID-19).
de Alencar JCG, Moreira CL, Müller AD, Chaves CE, Fukuhara MA, da Silva EA, Miyamoto MFS, Pinto VB, Bueno CG, Lazar Neto F, Gomez Gomez LM, Menezes MCS, Marchini JFM, Marino LO, Brandão Neto RA, Souza HP; COVID Register Group. de Alencar JCG, et al. Clin Infect Dis. 2021 Jun 1;72(11):e736-e741. doi: 10.1093/cid/ciaa1443. Clin Infect Dis. 2021. PMID: 32964918 Free PMC article. Clinical Trial.
BACKGROUND: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may induce a redox imbalance in alveolar epithelium cells, causing apoptosis, increased inflammation and, consequent …
BACKGROUND: A local increase in angiotensin 2 after inactivation of angiotensin-converting enzyme 2 by severe acute respiratory syndrome cor …
N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence.
Ooi SL, Green R, Pak SC. Ooi SL, et al. Biomed Res Int. 2018 Oct 22;2018:2469486. doi: 10.1155/2018/2469486. eCollection 2018. Biomed Res Int. 2018. PMID: 30426004 Free PMC article.
Good evidence exists to support the use of N-acetylcysteine as an adjunct treatment to reduce the total and negative symptoms of schizophrenia. ...Larger and better-designed studies are required to further investigate the clinical effectiveness of N-acetylcysteine i …
Good evidence exists to support the use of N-acetylcysteine as an adjunct treatment to reduce the total and negative symptoms of schi …
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure.
Lee WM, Hynan LS, Rossaro L, Fontana RJ, Stravitz RT, Larson AM, Davern TJ 2nd, Murray NG, McCashland T, Reisch JS, Robuck PR; Acute Liver Failure Study Group. Lee WM, et al. Gastroenterology. 2009 Sep;137(3):856-64, 864.e1. doi: 10.1053/j.gastro.2009.06.006. Epub 2009 Jun 12. Gastroenterology. 2009. PMID: 19524577 Free PMC article. Clinical Trial.
BACKGROUND & AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen-related acute liver failure. ...
BACKGROUND & AIMS: N-acetylcysteine (NAC), an antidote for acetaminophen poisoning, might benefit patients with non-acetaminophen …
N-acetylcysteine for non-paracetamol (acetaminophen)-related acute liver failure.
Siu JT, Nguyen T, Turgeon RD. Siu JT, et al. Cochrane Database Syst Rev. 2020 Dec 9;12(12):CD012123. doi: 10.1002/14651858.CD012123.pub2. Cochrane Database Syst Rev. 2020. PMID: 33294991 Free PMC article.
OBJECTIVES: To assess the benefits and harms of N-acetylcysteine compared with placebo or no N-acetylcysteine, as an adjunct to usual care, in people with non-paracetamol-related acute liver failure. ...For all-cause mortality at 21 days between adults receiving N- …
OBJECTIVES: To assess the benefits and harms of N-acetylcysteine compared with placebo or no N-acetylcysteine, as an adjunct t …
Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis.
Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Cazzola M, et al. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Eur Respir Rev. 2015. PMID: 26324807 Free article. Review.
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), we have carried out a meta-analysis testing the available evidence that NAC treatment may be effective in …
In order to clarify the possible role of N-acetylcysteine (NAC) in the treatment of patients with chronic bronchitis and chronic obst …
Role of N-acetylcysteine treatment in non-acetaminophen-induced acute liver failure: A prospective study.
Nabi T, Nabi S, Rafiq N, Shah A. Nabi T, et al. Saudi J Gastroenterol. 2017 May-Jun;23(3):169-175. doi: 10.4103/1319-3767.207711. Saudi J Gastroenterol. 2017. PMID: 28611340 Free PMC article. Clinical Trial.
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and little is known about the use of N-acetylcysteine (NAC) in NAI-ALF. A randomized case control study was conducted with the aim to de …
To date, there is no established treatment for non-acetaminophen-induced acute liver failure (NAI-ALF) other than liver transplantation, and …
Pirfenidone plus inhaled N-acetylcysteine for idiopathic pulmonary fibrosis: a randomised trial.
Sakamoto S, Kataoka K, Kondoh Y, Kato M, Okamoto M, Mukae H, Bando M, Suda T, Yatera K, Tanino Y, Kishaba T, Hattori N, Taguchi Y, Saito T, Nishioka Y, Kuwano K, Kishi K, Inase N, Sasaki S, Takizawa H, Johkoh T, Sakai F, Homma S; Diffuse Lung Diseases Research Group of the Ministry of Health, Labour and Welfare, Japan. Sakamoto S, et al. Eur Respir J. 2021 Jan 5;57(1):2000348. doi: 10.1183/13993003.00348-2020. Print 2021 Jan. Eur Respir J. 2021. PMID: 32703779 Clinical Trial.
The incidence of adverse events (n=19 (55.9%) for pirfenidone plus N-acetylcysteine; n=18 (50%) for pirfenidone alone) was similar between groups. CONCLUSIONS: Combination treatment with inhaled N-acetylcysteine and pirfenidone is likely to result in worse outcomes …
The incidence of adverse events (n=19 (55.9%) for pirfenidone plus N-acetylcysteine; n=18 (50%) for pirfenidone alone) was similar be …
Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis.
Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Rogliani P, et al. Pulm Pharmacol Ther. 2016 Oct;40:95-103. doi: 10.1016/j.pupt.2016.07.009. Epub 2016 Jul 29. Pulm Pharmacol Ther. 2016. PMID: 27481628 Review.
The aim of this study was to assess the effectiveness and safety of the currently approved drugs for IPF and N-acetylcysteine (NAC), the most debated drug in the last update of guidelines for IPF treatment. ...
The aim of this study was to assess the effectiveness and safety of the currently approved drugs for IPF and N-acetylcysteine (NAC), …
N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial.
Grant JE, Chamberlain SR, Redden SA, Leppink EW, Odlaug BL, Kim SW. Grant JE, et al. JAMA Psychiatry. 2016 May 1;73(5):490-6. doi: 10.1001/jamapsychiatry.2016.0060. JAMA Psychiatry. 2016. PMID: 27007062 Clinical Trial.
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or placebo was administered for 12 weeks. ...Compared with placebo, N-acetylcysteine treatment was associated with significant improvements …
Data analysis was performed from July 16 to September 9, 2015. INTERVENTIONS: N-acetylcysteine (dosing range, 1200-3000 mg/d) or plac …
Glucocorticoids plus N-acetylcysteine in severe alcoholic hepatitis.
Nguyen-Khac E, Thevenot T, Piquet MA, Benferhat S, Goria O, Chatelain D, Tramier B, Dewaele F, Ghrib S, Rudler M, Carbonell N, Tossou H, Bental A, Bernard-Chabert B, Dupas JL; AAH-NAC Study Group. Nguyen-Khac E, et al. N Engl J Med. 2011 Nov 10;365(19):1781-9. doi: 10.1056/NEJMoa1101214. N Engl J Med. 2011. PMID: 22070475 Free article. Clinical Trial.
We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS: We randomly assigned 174 patients to receive prednisolone plus N-acetylcysteine (85 patients) or only prednisolone (89 patients). ...RESULTS: Mort …
We investigated whether combination therapy with glucocorticoids plus N-acetylcysteine would improve survival. METHODS: We randomly a …
1,019 results